Allarity Therapeutics, Inc. (ALLR)
NASDAQ: ALLR · Real-Time Price · USD
1.050
0.00 (0.00%)
Jan 21, 2025, 4:00 PM EST - Market closed
Allarity Therapeutics Employees
As of December 31, 2023, Allarity Therapeutics had 6 total employees, including 5 full-time and 1 part-time employees. The number of employees decreased by 3 or -33.33% compared to the previous year.
Employees
6
Change (1Y)
-3
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$3,237,167
Market Cap
4.66M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
ALLR News
- 2 days ago - Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 6 days ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Reach Out - Accesswire
- 9 days ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Allarity Therapeutics, Inc. (ALLR) And Encourages Stockholders to Connect - Accesswire
- 13 days ago - Allarity Therapeutics, Inc. (ALLR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Accesswire
- 16 days ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Allarity Therapeutics, Inc. (ALLR) and Encourages Stockholders to Learn More About the Investigation - Accesswire
- 22 days ago - Bronstein, Gewirtz & Grossman, LLC Encourages Allarity Therapeutics, Inc. (ALLR) Investors to Inquire about Securities Investigation - Accesswire
- 6 weeks ago - Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion - GlobeNewsWire
- 2 months ago - Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements - GlobeNewsWire